Landmark detection via convolutional neural network
Prostate cancer is the fourth most common cancer diagnosis in worldwide, with around 1.4 million new cases and 370 000 deaths in 2020. If prostate cancer is suspected, the following procedures may be used to decide if more diagnostic tests are needed: prostate-specific antigen (PSA) test, digital rectal exam (DRE), etc. Then further tests will be used to confirm whether a person has prostate cancer on condition that the PSA or DRE test results are abnormal. Many tests can suggest that cancer is present, but only a biopsy can make a definite diagnosis. The recent introduction of multiparametric magnetic resonance imaging (MP-MRI) now allows for imaging-based identification of prostate cancer, which may improve diagnostic accuracy for higher-risk tumors. Targeted MR/ultrasound (US) fusion biopsy is a breakthrough technology made possible by overlaying ultrasound images of the prostate with MRI sequences for visualization and targeting lesions. Suspect areas detected by the MRI are thereby displayed on the ultrasound scanner, allowing the urologist to target the necessary biopsies in real-time. Detecting 3D anatomical landmarks on both image modalities is a crucial step for targeted MR/US fusion biopsy. However, manually landmarking in 3D MR/US images is tedious, time-consuming, and lacks reproducibility. Therefore, a fast, accurate, and automatic 3D landmark detection system is meaningful for clinical applications. In this presentation, we will introduce various methods for landmark detection, and show some primary results for MR/US prostate anatomical landmark detection based on a database from cooperating company.